WO1995027062A1 - Agonist antibodies against the flk2/flt3 receptor and uses thereof - Google Patents

Agonist antibodies against the flk2/flt3 receptor and uses thereof Download PDF

Info

Publication number
WO1995027062A1
WO1995027062A1 PCT/US1995/003718 US9503718W WO9527062A1 WO 1995027062 A1 WO1995027062 A1 WO 1995027062A1 US 9503718 W US9503718 W US 9503718W WO 9527062 A1 WO9527062 A1 WO 9527062A1
Authority
WO
WIPO (PCT)
Prior art keywords
flk2
antibodies
flt3 receptor
agonist antibodies
antibodies against
Prior art date
Application number
PCT/US1995/003718
Other languages
French (fr)
Inventor
Brian D. Bennett
Susan D. Broz
William Matthews
Francis C. Zeigler
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to JP7525775A priority Critical patent/JPH09512163A/en
Priority to DE69509647T priority patent/DE69509647T2/en
Priority to EP95914185A priority patent/EP0754230B1/en
Priority to MX9604315A priority patent/MX9604315A/en
Publication of WO1995027062A1 publication Critical patent/WO1995027062A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.
PCT/US1995/003718 1994-04-04 1995-03-23 Agonist antibodies against the flk2/flt3 receptor and uses thereof WO1995027062A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP7525775A JPH09512163A (en) 1994-04-04 1995-03-23 Agonist antibody against flk2 / flt3 receptor and use thereof
DE69509647T DE69509647T2 (en) 1994-04-04 1995-03-23 AGONISTIC ANTIBODIES AGAINST THE FLK2 / FLT3 RECEPTOR AND THEIR USE
EP95914185A EP0754230B1 (en) 1994-04-04 1995-03-23 Agonist antibodies against the flk2/flt3 receptor and uses thereof
MX9604315A MX9604315A (en) 1994-04-04 1995-03-23 Agonist antibodies against the flk2/flt3 receptor and uses thereof.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/222,299 1994-04-04
US08/222,299 US5635388A (en) 1994-04-04 1994-04-04 Agonist antibodies against the flk2/flt3 receptor and uses thereof

Publications (1)

Publication Number Publication Date
WO1995027062A1 true WO1995027062A1 (en) 1995-10-12

Family

ID=22831684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003718 WO1995027062A1 (en) 1994-04-04 1995-03-23 Agonist antibodies against the flk2/flt3 receptor and uses thereof

Country Status (7)

Country Link
US (2) US5635388A (en)
EP (1) EP0754230B1 (en)
JP (1) JPH09512163A (en)
CA (1) CA2185211A1 (en)
DE (1) DE69509647T2 (en)
MX (1) MX9604315A (en)
WO (1) WO1995027062A1 (en)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
WO1999010494A2 (en) * 1997-08-25 1999-03-04 Genentech, Inc. Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
EP1047942A1 (en) * 1998-01-23 2000-11-02 Prolifaron, Inc. Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
WO2005058937A2 (en) 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
WO2007056470A2 (en) 2005-11-08 2007-05-18 Genentech, Inc. Neuropilin antagonists
EP1950300A2 (en) 1998-11-18 2008-07-30 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP2058334A2 (en) 1998-06-12 2009-05-13 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
US7691977B2 (en) 2003-08-01 2010-04-06 Genentech, Inc. Anti-VEGF antibodies
WO2010075420A1 (en) 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2011008696A2 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
WO2011032013A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
US7910098B2 (en) 2007-11-30 2011-03-22 Genentech, Inc. Anti-VEGF antibodies
WO2011033006A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
WO2011106300A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
US8071099B2 (en) 2008-05-30 2011-12-06 ImClone, LLC Anti-FLT3 antibodies
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
WO2012010547A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
WO2012010549A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012068030A1 (en) 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013083499A1 (en) 2011-12-05 2013-06-13 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2013112467A1 (en) 2012-01-23 2013-08-01 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
WO2013135602A2 (en) 2012-03-13 2013-09-19 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2014001232A1 (en) 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2014025813A1 (en) 2012-08-07 2014-02-13 Genentech, Inc. Combination therapy for the treatment of glioblastoma
EP2752189A1 (en) 2008-11-22 2014-07-09 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
WO2015031782A1 (en) 2013-08-30 2015-03-05 Genentech, Inc. Combination therapy for the treatment of glioblastoma
WO2015031808A2 (en) 2013-08-30 2015-03-05 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US8993249B2 (en) 2010-07-09 2015-03-31 Genentech, Inc. Anti-neuropilin antibodies and methods of use
WO2015089375A1 (en) 2013-12-13 2015-06-18 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2016077381A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2016106340A2 (en) 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
EP3095455A1 (en) 2006-12-19 2016-11-23 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2017181111A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
EP3252171A1 (en) 2013-05-23 2017-12-06 Five Prime Therapeutics, Inc. Methods of treating cancer
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US10072075B2 (en) 2015-09-23 2018-09-11 Genentech, Inc. Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
WO2020128638A1 (en) * 2018-12-18 2020-06-25 Northern Biologics Inc. Flt3 agonist antibodies and uses thereof
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3922649A1 (en) 2015-10-30 2021-12-15 F. Hoffmann-La Roche AG Anti-htra1 antibodies and methods of use thereof
WO2022103905A1 (en) 2020-11-13 2022-05-19 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
US11370833B2 (en) 2014-09-15 2022-06-28 Genentech, Inc. Antibody formulations
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
WO2023010095A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023145834A1 (en) 2022-01-27 2023-08-03 中外製薬株式会社 Anti-pd-l1 antibody-containing pharmaceutical composition used in combination with anti-vegf antibodies and paclitaxel
US12121586B2 (en) 2020-12-21 2024-10-22 Genentech, Inc. Optimized variants of anti-VEGF antibodies

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ307995A3 (en) 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US7361330B2 (en) 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
DE69940158D1 (en) * 1998-08-20 2009-02-05 Chugai Pharmaceutical Co Ltd METHOD FOR SCREENING POTENTIAL COMPOUNDS FOR DETECTING AN ANTI-TUMOR MEDICAMENT
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
US6576812B1 (en) 1999-05-06 2003-06-10 The Trustees Of Columbia University In The City Of New York Compound screening assays using a transgenic mouse model of human skin diseases
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
US7183385B2 (en) * 2002-02-20 2007-02-27 Cell Signaling Technology, Inc. Phospho-specific antibodies to Flt3 and uses thereof
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
WO2004106515A1 (en) * 2003-05-28 2004-12-09 Scimedia Ltd. Anti-bambi antibody and diagnostic or remedy for colon cancer and liver cancer containing the same
EP1670492A4 (en) * 2003-09-29 2009-07-08 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
WO2006116793A1 (en) 2005-05-04 2006-11-09 Australian Stem Cell Centre Limited Selecting, culturing and creating lineage committed hematopoietic stem cells
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
KR20180053744A (en) 2015-09-23 2018-05-23 사이토이뮨 테라퓨틱스 엘엘씨 FLT3-induced CAR cells for immunotherapy
SI3380620T1 (en) 2015-11-23 2024-09-30 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
WO2017193009A1 (en) * 2016-05-05 2017-11-09 Transfusion Health, Llc Maintenance, enrichment, enhancement and expansion of human hematopoietic stem cells
WO2017219029A2 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+cells
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
SG10202102897PA (en) 2017-01-20 2021-04-29 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
ES2912408T3 (en) 2017-01-26 2022-05-25 Novartis Ag CD28 compositions and methods for therapy with chimeric receptors for antigens
CN110582509A (en) 2017-01-31 2019-12-17 诺华股份有限公司 Treatment of cancer using chimeric T cell receptor proteins with multispecific properties
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
RU2020116579A (en) 2017-10-25 2021-11-25 Новартис Аг METHODS FOR OBTAINING CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
KR20210106437A (en) 2018-12-20 2021-08-30 노파르티스 아게 Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528A (en) 2019-02-15 2021-10-08 诺华股份有限公司 3- (1-oxo-5- (piperidine-4-yl) isoindoline-2-yl) piperidine-2, 6-dione derivatives and uses thereof
EP3962527A4 (en) 2019-04-30 2023-11-01 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
MX2022007759A (en) 2019-12-20 2022-07-19 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome.
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
CN115916199A (en) 2020-06-23 2023-04-04 诺华股份有限公司 Dosing regimens comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022104061A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN118056008A (en) 2021-04-27 2024-05-17 诺华股份有限公司 Virus vector production system
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001576A1 (en) * 1992-07-09 1994-01-20 Systemix, Inc. Novel flk-2 and analogs
WO1995007348A1 (en) * 1993-09-08 1995-03-16 Imclone Systems Incorporated Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition
US5367057A (en) * 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
WO1993010136A1 (en) * 1991-11-15 1993-05-27 The Trustees Of Princeton University Totipotent hematopoietic stem cell receptors and their ligands
US5672346A (en) * 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001576A1 (en) * 1992-07-09 1994-01-20 Systemix, Inc. Novel flk-2 and analogs
WO1995007348A1 (en) * 1993-09-08 1995-03-16 Imclone Systems Incorporated Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F. ZEIGLER ET AL.: "Cellular and molecular characterization of the role of the FLK-2/FLT3 receptor tyrosine kinase in hematopoietic stem cells.", BLOOD, vol. 84, no. 8, 15 October 1994 (1994-10-15), NEW YORK NY, USA, pages 2422 - 2430 *

Cited By (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
WO1999010494A2 (en) * 1997-08-25 1999-03-04 Genentech, Inc. Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
WO1999010494A3 (en) * 1997-08-25 1999-05-20 Genentech Inc Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1047942A1 (en) * 1998-01-23 2000-11-02 Prolifaron, Inc. Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
EP1047942A4 (en) * 1998-01-23 2002-10-30 Alexion Antibody Technologies Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
EP2058334A2 (en) 1998-06-12 2009-05-13 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
EP1950300A2 (en) 1998-11-18 2008-07-30 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US8084258B2 (en) 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
US9353177B2 (en) 2003-08-01 2016-05-31 Genentech, Inc. Anti-VEGF antibodies
US7691977B2 (en) 2003-08-01 2010-04-06 Genentech, Inc. Anti-VEGF antibodies
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US7811785B2 (en) 2003-08-01 2010-10-12 Genentech, Inc. Anti-VEGF antibodies
US8975381B2 (en) 2003-08-01 2015-03-10 Genentech, Inc. Anti-VEGF antibodies
EP2420512A2 (en) 2003-08-01 2012-02-22 Genentech, Inc. Anti-VEGF antibodies
US9018357B2 (en) 2003-08-01 2015-04-28 Genentech, Inc. Anti-VEGF antibodies
US8512699B2 (en) 2003-08-01 2013-08-20 Genentech, Inc. Anti-VEGF antibodies
US8492527B2 (en) 2003-08-01 2013-07-23 Genentech, Inc. Anti-VEGF antibodies
WO2005058937A2 (en) 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
EP3653641A1 (en) 2004-02-19 2020-05-20 Genentech, Inc. Cdr-repaired antibodies
US8795660B2 (en) 2005-11-08 2014-08-05 Genentech, Inc. Neuropilin antagonists
US7994286B2 (en) 2005-11-08 2011-08-09 Genentech, Inc. Neuropilin antagonists
EP2570434A2 (en) 2005-11-08 2013-03-20 Genentech, Inc. Neuropilin antagonists
US8378080B2 (en) 2005-11-08 2013-02-19 Genentech, Inc. Neuropilin antagonists
US8211429B2 (en) 2005-11-08 2012-07-03 Genetech, Inc. Neuropilin antagonists
WO2007056470A2 (en) 2005-11-08 2007-05-18 Genentech, Inc. Neuropilin antagonists
US10557118B2 (en) 2006-03-17 2020-02-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US9856453B2 (en) 2006-03-17 2018-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US10214726B2 (en) 2006-03-17 2019-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
EP3095455A1 (en) 2006-12-19 2016-11-23 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
US8921537B2 (en) 2007-11-30 2014-12-30 Genentech, Inc. Anti-VEGF antibodies
US7910098B2 (en) 2007-11-30 2011-03-22 Genentech, Inc. Anti-VEGF antibodies
US9777059B2 (en) 2007-11-30 2017-10-03 Genentech, Inc. Anti-VEGF antibodies
US8071099B2 (en) 2008-05-30 2011-12-06 ImClone, LLC Anti-FLT3 antibodies
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
EP3178478A1 (en) 2008-11-22 2017-06-14 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
EP2752189A1 (en) 2008-11-22 2014-07-09 F. Hoffmann-La Roche AG Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
WO2010075420A1 (en) 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
WO2011008696A2 (en) 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
WO2011032013A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
WO2011033006A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
EP3616719A1 (en) 2009-12-21 2020-03-04 F. Hoffmann-La Roche AG Antibody formulation
WO2011084750A1 (en) 2009-12-21 2011-07-14 Genentech, Inc. Antibody formulation
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
US9266948B2 (en) 2009-12-23 2016-02-23 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
EP3064509A2 (en) 2010-02-23 2016-09-07 F. Hoffmann-La Roche AG Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2011106300A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
EP3696194A1 (en) 2010-02-23 2020-08-19 F. Hoffmann-La Roche AG Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
US8993249B2 (en) 2010-07-09 2015-03-31 Genentech, Inc. Anti-neuropilin antibodies and methods of use
EP2848939A1 (en) 2010-07-19 2015-03-18 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010551A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010547A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2824457A1 (en) 2010-07-19 2015-01-14 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2801826A1 (en) 2010-07-19 2014-11-12 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010550A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010548A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2866032A1 (en) 2010-07-19 2015-04-29 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2848940A1 (en) 2010-07-19 2015-03-18 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012010549A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
WO2012012750A1 (en) 2010-07-23 2012-01-26 Trustees Of Boston University ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
EP3696195A1 (en) 2010-07-23 2020-08-19 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
WO2012068030A1 (en) 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
WO2012068032A1 (en) 2010-11-15 2012-05-24 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013083499A1 (en) 2011-12-05 2013-06-13 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2013112467A1 (en) 2012-01-23 2013-08-01 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
WO2013135602A2 (en) 2012-03-13 2013-09-19 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
EP3553083A1 (en) 2012-03-13 2019-10-16 F. Hoffmann-La Roche AG Combination therapy for the treatment of ovarian cancer
EP3556776A1 (en) 2012-05-31 2019-10-23 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
WO2014001232A1 (en) 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2014025813A1 (en) 2012-08-07 2014-02-13 Genentech, Inc. Combination therapy for the treatment of glioblastoma
EP3446709A1 (en) 2012-08-07 2019-02-27 F. Hoffmann-La Roche AG Combination therapy for the treatment of glioblastoma
US10010611B2 (en) 2013-03-13 2018-07-03 Genentech, Inc. Antibody formulations
US10925966B2 (en) 2013-03-13 2021-02-23 Genentech, Inc. Antibody formulations
EP3744345A1 (en) 2013-03-13 2020-12-02 F. Hoffmann-La Roche AG Antibody formulations
WO2014160490A1 (en) 2013-03-13 2014-10-02 Genetech, Inc. Antibody formulations
EP3252171A1 (en) 2013-05-23 2017-12-06 Five Prime Therapeutics, Inc. Methods of treating cancer
WO2015031782A1 (en) 2013-08-30 2015-03-05 Genentech, Inc. Combination therapy for the treatment of glioblastoma
WO2015031808A2 (en) 2013-08-30 2015-03-05 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2015089375A1 (en) 2013-12-13 2015-06-18 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US10240207B2 (en) 2014-03-24 2019-03-26 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
US10730951B2 (en) 2014-03-31 2020-08-04 Genentech, Inc. Anti-OX40 antibodies and methods of use
US9975957B2 (en) 2014-03-31 2018-05-22 Genentech, Inc. Anti-OX40 antibodies and methods of use
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US10208355B2 (en) 2014-07-14 2019-02-19 Genentech, Inc. Method of treatment for glioblastoma by administering a VEGF antagonist
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US11370833B2 (en) 2014-09-15 2022-06-28 Genentech, Inc. Antibody formulations
WO2016077381A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
EP3783023A1 (en) 2014-11-10 2021-02-24 H. Hoffnabb-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
WO2016106340A2 (en) 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
US10072075B2 (en) 2015-09-23 2018-09-11 Genentech, Inc. Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
US10899828B2 (en) 2015-09-23 2021-01-26 Genentech, Inc. Optimized variants of anti-vegf antibodies and methods of use thereof in treatment
US10906968B2 (en) 2015-09-23 2021-02-02 Genentech, Inc. Polynucleotides encoding optimized variants of anti-VEGF antibodies
EP3922649A1 (en) 2015-10-30 2021-12-15 F. Hoffmann-La Roche AG Anti-htra1 antibodies and methods of use thereof
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
WO2017181111A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2020081767A1 (en) 2018-10-18 2020-04-23 Genentech, Inc. Diagnostic and therapeutic methods for sarcomatoid kidney cancer
WO2020128638A1 (en) * 2018-12-18 2020-06-25 Northern Biologics Inc. Flt3 agonist antibodies and uses thereof
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11760797B2 (en) 2020-03-13 2023-09-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2022103905A1 (en) 2020-11-13 2022-05-19 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors
US12121586B2 (en) 2020-12-21 2024-10-22 Genentech, Inc. Optimized variants of anti-VEGF antibodies
WO2022232503A1 (en) 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023279092A2 (en) 2021-07-02 2023-01-05 Genentech, Inc. Methods and compositions for treating cancer
WO2023010095A1 (en) 2021-07-28 2023-02-02 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023145834A1 (en) 2022-01-27 2023-08-03 中外製薬株式会社 Anti-pd-l1 antibody-containing pharmaceutical composition used in combination with anti-vegf antibodies and paclitaxel

Also Published As

Publication number Publication date
DE69509647T2 (en) 1999-10-07
US5635388A (en) 1997-06-03
JPH09512163A (en) 1997-12-09
EP0754230A1 (en) 1997-01-22
MX9604315A (en) 1997-06-28
DE69509647D1 (en) 1999-06-17
CA2185211A1 (en) 1995-10-12
EP0754230B1 (en) 1999-05-12
US5997865A (en) 1999-12-07

Similar Documents

Publication Publication Date Title
WO1995027062A1 (en) Agonist antibodies against the flk2/flt3 receptor and uses thereof
Campioni et al. A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs
Tholpady et al. Mesenchymal stem cells from rat visceral fat exhibit multipotential differentiation in vitro
Bal et al. Antigen presentation by keratinocytes induces tolerance in human T cells
Formigli et al. Dermal matrix scaffold engineered with adult mesenchymal stem cells and platelet‐rich plasma as a potential tool for tissue repair and regeneration
MX9604316A (en) Protein tyrosine kinase agonist antibodies.
Schieker et al. Human mesenchymal stem cells at the single‐cell level: simultaneous seven‐colour immunofluorescence
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
PT1612265E (en) Bioengineered tissue constructs and methods for producing and using them
WO1994015958A3 (en) Peptide inhibitors of cell adhesion
Tiwari et al. Ex vivo expansion of haematopoietic stem/progenitor cells from human umbilical cord blood on acellular scaffolds prepared from MS‐5 stromal cell line
CA2079585A1 (en) Ligand for the neu gene product
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
MY148759A (en) Methods to culture circovirus
BR9306345A (en) Methods to suppress the ability of a mammal's t-cells to proliferate and to suppress immune response compositions for use in suppressing the ability of t-cells to proliferate and in suppressing the immune response
Campioni et al. Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment
Carson et al. Cell surface glycoconjugates as modulators of embryo attachment to uterine epithelial cells
Bocelli‐Tyndall et al. Human articular chondrocytes suppress in vitro proliferation of anti‐CD3 activated peripheral blood mononuclear cells
Kubo et al. c‐Kit+ Bone Marrow Stem Cells Differentiate into Functional Cardiac Myocytes
BR9815440A (en) Viable parasitic intestinal cells isolated
Boraschi et al. Regulation of macrophage suppression and cytotoxicity by interferon role of Ia-bearing macrophages.
AU1955899A (en) Mammalian edg-7 receptor homologs
ES2079690T3 (en) MAMMAL CELLS EXPRESSING A HYBRID RECEIVER.
Goldminz et al. Keratinocyte membrane-associated epidermal cell-derived thymocyte-activating factor (ETAF)
WO2001028574A3 (en) Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP MX

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2185211

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995914185

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1996/004315

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1995914185

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995914185

Country of ref document: EP